Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now Jun 12, 2024 07:00AM
Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now Jun 11, 2024 07:00AM
SeaStar Medical Granted Canadian Patent with Broad Claims Covering the Selective Cytopheretic Device Technology Feb 1, 2024 08:30AM
SeaStar Medical (ICU) Prices 10.84M Share Offering at $0.83/sh Jan 26, 2024 08:05AM
SeaStar Medical Announces Pricing of $9.0 Million Registered Direct Offering Priced At-the-Market Jan 26, 2024 08:05AM
View Older Stories

Jan 11, 2024 04:06PM SeaStar Medical (ICU) Appoints David A. Green as CFO
Jan 11, 2024 04:05PM SeaStar Medical Appoints David A. Green as Chief Financial Officer
Jan 9, 2024 08:30AM SeaStar Medical Issued U.S. Patent with Broad Claims Covering Use of the Selective Cytopheretic Device for Multiple Clinical Indications
Dec 28, 2023 08:31AM SeaStar Medical (ICU) Updates Subject Enrollment in Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury
Dec 28, 2023 08:30AM SeaStar Medical Updates Subject Enrollment in its Pivotal Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury
Dec 13, 2023 08:30AM SeaStar Medical Forms Scientific Advisory Board of World-Renowned Pediatric and Adult Clinical Experts
Nov 14, 2023 04:04PM SeaStar Medical Reports Third Quarter 2023 Financial Results and Provides a Business Update
Oct 31, 2023 08:00AM Nuwellis’ Strategic Partner, SeaStar Medical, Receives FDA Approvable Letter for Its Pediatric Selective Cytopheretic Device
Oct 30, 2023 08:09AM SeaStar Medical (ICU) Announces FDA Issues Approvable Letter for SeaStar Medical’s Selective Cytopheretic Device for Pediatric Patients
Oct 30, 2023 08:00AM FDA Issues Approvable Letter for SeaStar Medical’s Selective Cytopheretic Device for Pediatric Patients
Oct 18, 2023 08:32AM SeaStar Medical (ICU) Announces FDA Grants its Selective Cytopheretic Device Breakthrough Device Designation for Hepatorenal Syndrome
Oct 18, 2023 08:30AM FDA Grants SeaStar Medical’s Selective Cytopheretic Device Breakthrough Device Designation for Hepatorenal Syndrome
Oct 5, 2023 08:30AM SeaStar Medical to Present at the Dawson James Small Cap Growth Conference on October 12, 2023
Oct 3, 2023 04:05PM SeaStar Medical Provides Regulatory Update Regarding Selective Cytopheretic Device Use in Pediatric Acute Kidney Injury Under a Humanitarian Device Exemption
Sep 29, 2023 08:30AM SeaStar Medical (ICU) Granted FDA Breakthrough Device Designation to Selective Cytopheretic Device for Cardiorenal Syndrome
Sep 29, 2023 08:30AM FDA Grants Breakthrough Device Designation to SeaStar Medical’s Selective Cytopheretic Device for Cardiorenal Syndrome
Aug 29, 2023 08:00AM Case Series of Three Critically Ill Children with Acute Kidney Injury Safely Treated with SeaStar Medical’s Selective Cytopheretic Device Published in the Journal Blood Purification
Aug 22, 2023 08:00AM SeaStar Medical to Hold Business Update Conference Call Today at 4:00 p.m. Eastern Time
Aug 14, 2023 04:35PM SeaStar Medical Reports Second Quarter 2023 Financial Results and Provides a Business Update
Jun 30, 2023 08:00AM SeaStar Medical to Sponsor the Critical Care Time Podcast Series Covering Vital Medical Issues for Healthcare Professionals Who Care for Critically Ill Patients
Jun 20, 2023 04:05PM First Patient Enrolled in SeaStar Medical’s Pivotal Clinical Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury
Jun 14, 2023 08:00AM SeaStar Medical to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 21, 2023
May 15, 2023 04:45PM SeaStar Medical Reports First Quarter 2023 Financial Results and Provides a Business Update
May 10, 2023 08:00AM SeaStar Medical to Present at the JMP Securities Life Sciences Conference on May 16, 2023
May 9, 2023 04:05PM SeaStar Medical Provides Regulatory Update Related to its HDE Application for Pediatric Selective Cytopheretic Device
Apr 19, 2023 08:00AM SeaStar Medical Announces Activation of First Clinical Site in Pivotal Trial with Selective Cytopheretic Device in Critically Ill Adults with Acute Kidney Injury
Mar 30, 2023 07:23PM SeaStar Medical Reports 2022 Financial Results and Provides a Business Update
Mar 21, 2023 07:00AM Presenting on the Emerging Growth Conference on March 22 Register Now
Mar 15, 2023 04:05PM SeaStar Medical to Present at the Emerging Growth Virtual Conference on March 22, 2023
Feb 24, 2023 08:05AM SeaStar Medical’s Selective Cytopheretic Device to be Featured at the 5th Chronic Kidney Disease Drug Development Summit
Feb 15, 2023 04:01PM SeaStar Medical (ICU) Announces Details of the Selective Cytopheretic Device Pivotal Study in Critically ill Adults with Acute Kidney Injury
Feb 15, 2023 04:01PM SeaStar Medical Announces Details of the Selective Cytopheretic Device Pivotal Study in Critically ill Adults with Acute Kidney Injury
Feb 14, 2023 04:05PM SeaStar Medical to Hold Business Update Conference Call on February 15, 2023
Feb 9, 2023 08:20AM SeaStar Medical (ICU) Receives FDA Approval to Begin Study with Selective Cytopheretic Device to Reduce Hyperinflammation in Adults with Acute Kidney Injury
Feb 9, 2023 08:19AM SeaStar Medical Receives FDA Approval to Begin Study with Selective Cytopheretic Device to Reduce Hyperinflammation in Adults with Acute Kidney Injury
Jan 31, 2023 08:00AM SeaStar Medical to Present at the Virtual Sequire Biotechnology Conference on February 2, 2023
Jan 9, 2023 08:26AM SeaStar Medical (ICU) Submits IDE for a Novel Therapy to Reduce Hyperinflammation in Adult Acute AK Patients
Jan 9, 2023 08:25AM SeaStar Medical Submits Investigational Device Exemption (IDE) Application to FDA to Study a Novel Therapy to Reduce Hyperinflammation in Adult Acute Kidney Injury Patients
Dec 29, 2022 01:34PM SeaStar Medical and Nuwellis Enter into a U.S. License and Distribution Agreement for SeaStar Medical’s Selective Cytopheretic Device (SCD) for Pediatric Acute Kidney Injury (AKI)
Dec 29, 2022 08:32AM SeaStar Medical (ICU) and Nuwellis Enter US License Deal for Selective Cytopheretic Device (SCD)
Dec 29, 2022 08:30AM SeaStar Medical and Nuwellis Enter into a U.S. License and Distribution Agreement for SeaStar Medical’s Selective Cytopheretic Device (SCD) for Pediatric Acute Kidney Injury (AKI)
Dec 2, 2022 09:05AM SeaStar Medical Bolsters Operational Expertise with Appointment of Thomas R. Mullen as Vice President of Operations and Product Development
Dec 2, 2022 09:05AM SeaStar Medical Bolsters Operational Expertise with Appointment of Thomas R. Mullen as Vice President of Operations and Product Development
Nov 29, 2022 09:05AM SeaStar Medical (ICU) Appoints Rick Barnett as Chairman of the Board of Directors
Nov 29, 2022 09:05AM SeaStar Medical Appoints Rick Barnett as Chairman of the Board of Directors
Nov 29, 2022 09:05AM SeaStar Medical Appoints Rick Barnett as Chairman of the Board of Directors
Nov 7, 2022 12:30PM SeaStar Medical’s Lead Product Candidate, the Selective Cytopheretic Device (SCD), Included in Consensus Statement for Pediatric Acute Kidney Injury in First Pediatric Acute Disease Quality Initiati
Nov 7, 2022 12:30PM SeaStar Medical’s Lead Product Candidate, the Selective Cytopheretic Device (SCD), Included in Consensus Statement for Pediatric Acute Kidney Injury in First Pediatric Acute Disease Quality Initiati
Nov 3, 2022 09:04AM SeaStar Medical (ICU) Reports Positive Interim Safety Findings from Ongoing Study Evaluating the Selective Cytopheretic Device (SCD) in Children
Nov 3, 2022 09:00AM SeaStar Medical (Nasdaq: ICU) Announces Positive Interim Safety Findings from Ongoing Study Evaluating the Selective Cytopheretic Device (SCD) in Children
View Older Stories